Similarly, CX3CR1 polymorphisms that decrease receptor activity or affinity for FKN are linked to enhanced disease progression in amyotrophic lateral sclerosis (Lopez-Lopez et al., 2014; Calvo et al., 2018), Alzheimer’s disease (Finneran and Nash, 2019) and neuroinflammatory pathologies (Arli et al., 2013; Cardona et al., 2018). Here, CX3CR1 is linked to amyotrophic lateral sclerosis.